Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 447

1.

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

Dahlberg SE, Shapiro GI, Clark JW, Johnson BE.

J Natl Cancer Inst. 2014 Jun 24;106(7). pii: dju163. doi: 10.1093/jnci/dju163. Print 2014 Jul.

PMID:
24963024
[PubMed - in process]
2.

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.

Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, Shapiro GI, Uronis H.

Invest New Drugs. 2014 Jun 11. [Epub ahead of print]

PMID:
24916770
[PubMed - as supplied by publisher]
3.

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation.

Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF.

Elife (Cambridge). 2014 May 29:e02872. doi: 10.7554/eLife.02872. [Epub ahead of print]

PMID:
24876129
[PubMed - as supplied by publisher]
Free PMC Article
4.

Bioimpedance phase angle predicts muscle function, quality of life and clinical outcome in maintenance hemodialysis patients.

Beberashvili I, Azar A, Sinuani I, Shapiro G, Feldman L, Stav K, Sandbank J, Averbukh Z.

Eur J Clin Nutr. 2014 Jun;68(6):683-9. doi: 10.1038/ejcn.2014.67. Epub 2014 Apr 16.

PMID:
24736681
[PubMed - in process]
5.

Multiple myeloma in the very old: an IASIA conference report.

Tuchman SA, Shapiro GR, Ershler WB, Badros A, Cohen HJ, Dispenzieri A, Flores IQ, Kanapuru B, Jurivich D, Longo DL, Nourbakhsh A, Palumbo A, Walston J, Yates JW.

J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju067. doi: 10.1093/jnci/dju067.

PMID:
24700806
[PubMed - indexed for MEDLINE]
6.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.

PMID:
24625776
[PubMed - in process]
7.

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.

Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP.

PLoS One. 2014 Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353. eCollection 2014.

PMID:
24618589
[PubMed - in process]
Free PMC Article
8.

Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.

Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):323-6; quiz 326.

PMID:
24616538
[PubMed - in process]
9.

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

Jänne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P, Felip E.

J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.

PMID:
24496004
[PubMed - in process]
10.

Longitudinal changes in bioimpedance phase angle reflect inverse changes in serum IL-6 levels in maintenance hemodialysis patients.

Beberashvili I, Azar A, Sinuani I, Kadoshi H, Shapiro G, Feldman L, Sandbank J, Averbukh Z.

Nutrition. 2014 Mar;30(3):297-304. doi: 10.1016/j.nut.2013.08.017.

PMID:
24484680
[PubMed - in process]
11.

Totally tourniquets. The facts & details about different types of tourniquets.

Smith ER, Shapiro GL.

JEMS. 2013 Nov;38(11):48, 50, 52.

PMID:
24475621
[PubMed - indexed for MEDLINE]
12.

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR.

J Thorac Oncol. 2013 Oct;8(10):1335-8. doi: 10.1097/JTO.0b013e3182a00f41.

PMID:
24457244
[PubMed - in process]
13.

Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.

Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel JB, Janne PA, Sharpless NE, Engelman JA, Shapiro GI, Kung AL, Wong KK.

Clin Cancer Res. 2014 Mar 1;20(5):1204-11. doi: 10.1158/1078-0432.CCR-13-1733. Epub 2013 Dec 10.

PMID:
24327273
[PubMed - in process]
14.

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC.

J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9.

PMID:
24323026
[PubMed - indexed for MEDLINE]
15.

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.

Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S.

Invest New Drugs. 2014 Jun;32(3):445-51. doi: 10.1007/s10637-013-0044-7. Epub 2013 Nov 24.

PMID:
24271274
[PubMed - in process]
16.

Tactical emergency casualty care?pediatric appendix: novel guidelines for the care of the pediatric casualty in the high-threat, prehospital environment.

Bobko J, Lai TT, Smith ER, Shapiro GL, Baldridge RT, Callaway DW.

J Spec Oper Med. 2013 Winter;13(4):94-107.

PMID:
24227567
[PubMed - in process]
17.

Psychosocial stress in pregnancy and preterm birth: associations and mechanisms.

Shapiro GD, Fraser WD, Frasch MG, Séguin JR.

J Perinat Med. 2013 Nov;41(6):631-45. doi: 10.1515/jpm-2012-0295. Review.

PMID:
24216160
[PubMed - indexed for MEDLINE]
18.

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J, Smith DL, Sang J, Bates RC, El-Hariry I.

Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.

PMID:
24173541
[PubMed - in process]
19.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.

Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G.

Clin Cancer Res. 2014 Jan 1;20(1):233-45. doi: 10.1158/1078-0432.CCR-13-1777. Epub 2013 Oct 28.

PMID:
24166903
[PubMed - in process]
20.

Q&A: Geoffrey Shapiro on phase I drug trials. Spoke with Suzanne Rose.

Shapiro G.

Cancer Discov. 2013 Oct;3(10):1089. doi: 10.1158/2159-8290.CD-ND2013-021. Epub 2013 Oct 3. No abstract available.

PMID:
24124216
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk